UNSPSC 51262306: Fiduxosin hydrochloride

This classification denotes an alpha-adrenergic blocking agent C30H29N5O4S.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UYV23L1N89, chemically known as pyrazino(2',3':4,5)thieno(3,2-d)pyrimidine-2,4(1h,3h)-dione, 8-phenyl-3-(4-((3ar,9br)-1,3a,4,9b-tetrahydro-9-methoxy(1)benzopyrano(3,4-c)pyrrol-2(3h)-yl)butyl)-, monohydrochloride, but more generally known as fiduxosin hydrochloride, which bears US NIH Compound Identifier 172306.

Most nations, for tariff and trade purposes, schedule fiduxosin hydrochloride under HS 29349990 and SITC 51579. As of Q4 2014, FIDUXOSIN HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Fiduxosin hydrochloride bears US NLM identifiers UMLS ID C2825597 and NCI Concept Code C81371. SMILES: COC1CCCC2C1[C@@H]3CN(C[C@@H]3CO2)CCCCN4C(=O)C5C(C6C(S5)NCC(N6)C7CCCCC7)[NH]C4=O.CL.

UNSPSC 51262306 Fiduxosin hydrochloride is a Commodity code with minimal recent state and local procurement activity that matches its nominal scope. The two recent opportunities tagged under this code diverge sharply from the pharmaceutical product itself: Seminole County, Florida's IFB60459723LAS solicits naloxone and drug deactivation systems for community health delivery, and the Texas Health and Human Services Commission's RFI HHS0017013 seeks vendor capabilities for a direct-to-manufacturer prescription program. Neither opportunity involves fiduxosin hydrochloride or pharmaceuticals at the ingredient or active-agent level. The mismatch between the code name and actual solicitations suggests either tagging inconsistency in the source systems or that state and local procurement offices are using broader pharmaceutical-related codes to flag diverse health-related acquisitions.

The issuing bodies include a county health department (Seminole County) and a state health agency (Texas HHS). The Seminole County IFB, posted June 30, 2026 with a response deadline of July 26, 2023 (note: the deadline precedes the posting date in the source), seeks competitive bids for naloxone and safe drug deactivation systems on an annual basis with quarterly deliveries. The Texas RFI, posted April 3, 2026, represents early-stage market research with no formal award timeline or budget identified. Geographic activity is limited to Florida and Texas in the recent record. The code shows no established pattern of repeat buyers or sustained procurement activity aligned with fiduxosin hydrochloride itself.